RxDoctor Payments Data

Rhea Douglas

Medical · Decatur, GANPI 1023247210

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,682 of the $12,754 with a category attached, or 60.2%. 25 manufacturers reported payments, led by Sanofi at 28.0% of the total. 2025 is the largest year on record at $6,426, 9.8 times the $655 reported in 2021. Among medical clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,754in general payments, 2019–2025

Across 198 payments — averaging $64.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$4K
  • UCB, Inc.$2K
  • Arcutis Biotherapeutics, Inc.$2K
  • Novartis$926
  • Dermavant Sciences, Inc.$778
  • AbbVie$770
  • plus $4K from 19 others

What the payments were for

  • Consulting fees$2,34018%
  • Speaking & faculty fees$2,63221%
  • Food & beverage$7,68260%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,754 in reported general payments places this provider in the 95th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$115,586
Medicare patients
523
Services billed
2,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib11$68,771
Clobetasol Propionate71$2,717
Tacrolimus16$2,082
Ketoconazole160$2,016
Tretinoin14$1,459
Metronidazole27$1,341
Clindamycin Phosphate39$1,314
Fluorouracil12$791
Doxycycline Hyclate26$505
Fluocinonide11$499
Ciclopirox18$470
Triamcinolone Acetonide52$401
Mometasone Furoate18$381
ValacyclovirValacyclovir Hcl14$375
CiclopiroxCiclopirox Olamine33$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$770$68,77111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 950 medical providers in Georgia.

Other medical in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →